FindTrial
Sign In

A study to compare the reduction in blood pressure benefits of 2 drugs Azilsartan and Cilnidipine in sugar patients.

A clinical study to compare the antihypertensive benefits of Cilnidipine & Azilsartan in T2DM patients. - not applicable

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019168
Enrollment
64
Registered
2019-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: -

Interventions

Intervention1: TABLET.CILNIDIPINE 5-10MG OD FOR 3 MONTHS: TO compare the Antihypertensive benefits of AZILSARTAN and CILNIDIPINE in TYPE 2 DIABETES MELLITUS patients cardiac and renal outcome Interven

Sponsors

Dr SHAMEEMUNISHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with Type 2 Diabetes Mellitus > 2years duration on medical treatment with newly diagnosed Simple Hypertension (JNC8) 2.Male and Female 3.Age >40 years 4.Outpatient from Department of General Medicine. 5.BMI up to type I obesity (30-40) 6.All DM patients on OHA either single /double/triple/insulin

Exclusion criteria

Exclusion criteria: 1.Renal dysfunction, 2.Patients on NSAIDS, STATIN, ASPIRIN, Immunomodulators , alternative medicines 3.Hepatic dysfunction 4.Cardiac abnormalities 5.Pregnancy and lactating women 6.Inpatients 7.ICU patients 8.EMD patients 9.Serious infections 10.PVD 11.H/o Smoking,Alcohol

Design outcomes

Primary

MeasureTime frame
To observe the antihypertensive benefit of Azilsartan and Cilnidipine in type 2 diabetes hypertensive patientââ?¬â?¢s cardiac and renal parameters Timepoint: PREMEDICATION PARAMETERS FBS,PPBS,hsCRP,eGFR,BP,BMI,LIPID PROFILE- WILL BE DONE 1 DAY PRIOR TO INITIATING MEDICATION—

Secondary

MeasureTime frame
To compare Azilsartan and Cilnidipine protective effects on cardiac(hsCRP) and renal risk factors (eGFR) Timepoint: POST MEDICATION PARAMETERS FBS,PPBS,hsCRP,eGFR,BP,BMI,LIPID PROFILE- AFTER 3 MONTHS OF MEDICATION PERIOD 1 DAY LATER PARAMETERS WILL BE DONE—

Countries

India

Contacts

Public ContactDr K BHUVANESWARI

PSG INSTITUTE OF MEDICAL SCIENCES AND RESEARCH

nandabhuvana@gmail.com919894769934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026